Sign In
Buy DOCS
$21.04
-0.470 (-2.19%)
At Close: Jun 03, 2026
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
11:56am, Monday, 23'rd Dec 2024
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
This Health Care Software Firm Nears Buy Point After Whopping 101% Year-To-Date Gain
03:20pm, Friday, 20'th Dec 2024
Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point.
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on b
Doximity initiated with an Equal Weight at Stephens
04:23pm, Thursday, 19'th Dec 2024
Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, thoug
Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care
08:00am, Tuesday, 17'th Dec 2024
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025
04:01pm, Monday, 16'th Dec 2024
The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.
Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
07:52am, Friday, 06'th Dec 2024
Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financ
Buy 5 High-Flying Health & Fitness Stocks of 2024 With More Upside
09:35am, Thursday, 05'th Dec 2024
Five Health & Fitness stocks have strong growth potential for 2025. These are GRMN, SFM, DOCS, PLNT and PTON.
Doximity initiated with a Neutral at Mizuho
04:31pm, Tuesday, 03'rd Dec 2024
Mizuho initiated coverage of Doximity with a Neutral rating and $55 price target. The company has witnessed some volatility in quarterly top-line growth over the past few years due to timing of pharma
Are Medical Stocks Lagging Doximity (DOCS) This Year?
03:27pm, Monday, 02'nd Dec 2024
Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.
Dr Martens redemption arc will be ‘multi-year event'
07:36am, Thursday, 28'th Nov 2024
The post-IPO narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it's easy to glance over the green shoots of optimism emerging from the business. Wh
Dr Martens shares booted higher despite swinging to a loss
04:34am, Thursday, 28'th Nov 2024
Dr Martens PLC (LSE:DOCS)'s double-digit revenue decline and pre-tax loss in the first half wasn't as bad as it seems, if the market's reaction is anything to go by. Shares in the shoe brand, which ha
Dr Martens delivers double-digit sales decline and jumbo pre-tax loss
03:12am, Thursday, 28'th Nov 2024
Dr Martens PLC (LSE:DOCS) had another unflattering trading performance in the first half of its financial year, with revenues declining 18% year-on-year to £325 million, in line with expectations. Th
Dr Martens set to unveil loss as all eyes on outlook in results
10:45am, Wednesday, 27'th Nov 2024
Dr Martens PLC (LSE:DOCS)'s first half results on Thursday, 28 November will likely be more about its outlook as a decline in sales and swing to loss are expected. According to Deutsche Bank analysts,
3 Momentum Anomaly Stocks to Buy as Election Rally Fizzles
09:56am, Tuesday, 19'th Nov 2024
DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
